Seaport Therapeutics, Inc.

Filing Date

Apr 30, 2026

Transaction Date

Apr 30, 2026

Accession Number

0001193125-26-198522

Form Type

3

Footnotes

1. (F1)Each share of Series B Preferred Stock (the "Preferred Stock") is convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares shown in Column 3 without payment of further consideration. The Preferred Stock has no expiration date.
2. (F2)The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
3. (F3)1/4th of the shares underlying this option vested and became exercisable on November 7, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each vesting date.
4. (F4)The shares underlying this option are fully vested and exercisable.
5. (F5)The shares underlying this option shall vest in forty-eight (48) equal monthly installments following February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.